The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
HB

h.brandt

TL2 Moderator · Bergen

Contributes reviews on supplier material. Based in Bergen.

Joined 15 May 2025 · last posted 6d

78Posts here
4Topics
1Solutions
1.2kLikes received
1.2kLikes given
25Badges
215Days visited
5.2kPosts read

Most-liked posts

  • Coming back to: Why quantitation is the hard part, not detection Replied, post #28 · Analytics › Home & field testing · 18 Jun 2025 · 32 likes Immunoassay limitations: tests that use antibodies have cross-reactivity limitations. An antibody raised to semaglutide will cross-react to some degree with tirzepatide…
  • TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #48 · Compounds › Repair & healing peptides · 23 Jun 2025 · 31 likes The distinction between "no evidence it works" and "evidence it does not work": we have the first for these compounds. That is genuinely different from the second and…
  • [2026 update] What we do not know about retatrutide, listed explicitly Replied, post #41 · Compounds › Retatrutide · 9 Aug 2025 · 30 likes post #40 is right about the mechanism and I think understates the practical bit. Hepatic effects: glucagon receptor agonism promotes hepatic fat oxidation, which is…
  • About the Receptor biology category Replied, post #7 · Pharmacology › Receptor biology · 27 Jun 2026 · 28 likes Cross-reactivity and selectivity: the compounds are not perfectly selective for their target receptors. Semaglutide has some activity on other receptors; tirzepatide…
  • Reading a trial's population section before its results Replied, post #82 · Evidence › Trials · 3 Jun 2026 · 28 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
  • Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #9 · Compounds › Oral incretins · 18 Oct 2025 · 26 likes On post #5 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…

Where this member posts

CategoryPostsShare
Compounds1722%
Sourcing1114%
Analytics912%
Evidence810%
Practice810%
Pharmacology56%

Badges earned, in order

BadgeTierGranted
Basic Userbronze17 May 2025
Read the Guidelinesbronze17 May 2025
First Replybronze21 May 2025
First Topicbronze21 May 2025
Welcomebronze25 May 2025
First Quotebronze5 Jun 2025
First Linkbronze11 Jun 2025
Editorbronze12 Jun 2025
Asked Wellbronze15 Jun 2025
First Tagbronze27 Jun 2025
Memberbronze28 Jun 2025
Generousbronze14 Jul 2025
First Solutionbronze30 Jul 2025
Good Postsilver3 Aug 2025
Readerbronze8 Aug 2025
Thank Yousilver21 Aug 2025
Sourcedbronze6 Sep 2025
Promotedsilver20 Sep 2025
First Vendor Reportbronze3 Oct 2025
Nice Topicbronze28 Oct 2025
Nice Postbronze29 Oct 2025
De-escalatorgold3 Dec 2025
Consistently Generoussilver16 Dec 2025
Popular Linksilver1 Mar 2026
Anniversarysilver15 May 2026